OTC Regulatory Pathway Needs NDA Flexibility, Monograph Scope – Sharfstein
This article was originally published in The Tan Sheet
Executive Summary
Former FDA deputy commissioner Joshua Sharfstein, noting public health advocates’ disappointment with results from Sunscreen Innovation Act requirements, proposes an OTC drug review pathway that combines elements of the NDA and monograph systems and would require legislation to create.